Krause Daniela L, Müller Norbert
Department of Psychiatry and Psychotherapy, Ludwig-Maximilians University Munich, Nussbaumstr. 7, 80336 Munich, Germany.
Int J Alzheimers Dis. 2010 Jun 14;2010:732806. doi: 10.4061/2010/732806.
Neuroinflammation has been implicated in the pathology of Alzheimer's disease (AD) for decades. Still it has not been fully understood when and how inflammation arises in the course of AD. Whether inflammation is an underling cause or a resulting condition in AD remains unresolved. Mounting evidence indicates that microglial activation contributes to neuronal damage in neurodegenerative diseases. However, also beneficial aspects of microglial activation have been identified. The purpose of this review is to highlight new insights into the detrimental and beneficial role of neuroinflammation in AD. It is our intention to focus on newer controversies in the field of microglia activation. Precisely, we want to shed light on whether neuroinflammation is associated to brain tissue damage and functional impairment or is there also a damage limiting activity. In regard to this, we discuss the limitations and the advantages of anti-inflammatory treatment options and identify what future implications might result from this underling neuroinflammation for AD therapy.
几十年来，神经炎症一直被认为与阿尔茨海默病（AD）的病理过程有关。然而，在AD病程中炎症何时以及如何发生仍未完全明确。炎症究竟是AD的潜在病因还是结果仍未得到解决。越来越多的证据表明，小胶质细胞激活会导致神经退行性疾病中的神经元损伤。然而，小胶质细胞激活的有益方面也已被发现。本综述的目的是强调神经炎症在AD中有害和有益作用的新见解。我们打算关注小胶质细胞激活领域的新争议。确切地说，我们想阐明神经炎症是否与脑组织损伤和功能损害有关，或者是否也存在损伤限制活性。关于这一点，我们讨论抗炎治疗方案的局限性和优势，并确定这种潜在的神经炎症对AD治疗可能产生的未来影响。
